View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

Cleaner 2024 ahead

Q4 fell 17-18% short, we cut estimates 6-11%. The 20% Hearing Core adj EBITA margin target was not so firm. SOTP TP DKK 225 (240). Stock more investable today.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

Messy Q4, clear uplift in 2024

Many moving parts to Q4 margins, confirmation of demand trough. Leaving a weak 2023 behind with better visibility for 2024. BUY on cheap turnaround. TP DKK 240 (200) on rising peer valuations.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

A quiet quarter is good news for GN

An in-line quarter is good news for GN stock. Audio demand signals point to turnaround. Not valued for recovery, nor for structural values.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

Still unclear pace in near-term margin recovery

GN reports Q3 on Friday, 10 Nov @ 07:00 CET. Guidance likely to be tweaked both up & down. TP DKK 200 (215). BUY on skewed turnaround risk/reward.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Benjamin Silverstone
  • Morten Larsen

US Audio Enterprise business stabilising

Market overreacts to Audio guidance downgrade , in our view. Strong Hearing, US Enterprise stabilising, margins recovering. Core estimates unchanged, very attractive at 17x '24e P/E.

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Benjamin Silverstone
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Benjamin Silverstone
  • Morten Larsen

Q2 to show GN on path to normalization

Q2 stepping stone towards 20% margins. Scope for Hearing growth guidance hike, low Audio visibility. Good value on 2024e, Q2 to de-risk and bridge towards 2024.

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Benjamin Silverstone
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Benjamin Silverstone
  • Morten Larsen

De-risking Q1 puts spotlight on value — BUY

We are increasingly comfortable with GN fixing its debt problem. Up to BUY (Hold), TP of DKK 215 (175) after Q1 inflection point.

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Benjamin Silverstone
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Benjamin Silverstone
  • Morten Larsen
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch